Expertise in
15
conditions

Dr. Josephine H. Haduong

Pediatric Hematology Oncology
1201 West La Veta Avenue, 
Orange, CA 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Referral may be required
Before you request
Expertise in
15
conditions
1201 West La Veta Avenue, 
Orange, CA 

Overview

Josephine Haduong is a Pediatric Hematologist Oncology provider practicing medicine in Orange, California.

Dr. Haduong is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Rhabdomyosarcoma, Hepatoblastoma, Acute Lymphoblastic Leukemia (ALL), and Neuroblastoma.

She is actively involved in clinical research, co-authoring 15 peer reviewed articles and participating in 18 clinical trials. Dr. Haduong is currently accepting new patients.

Specialties

Pediatric Hematology Oncology

Licenses

Hospitalist in CA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
View 2 Less Insurance Carriers -

Locations

1201 West La Veta Avenue, Orange, CA 92868

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Phase 1/2 Study of DS-8201a (NSC# 807708) in Children, Adolescents, or Young Adults With Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
A Phase 1/2 Study of DS-8201a (NSC# 807708) in Children, Adolescents, or Young Adults With Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Biological
Study Drug: Trastuzumab Deruxtecan
Study Phase: Phase 2
A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Drug
Study Drug: Tegavivint
Study Phase: Phase 1/Phase 2
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma
Enrollment Status: Suspended
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure
Study Drug: FACT Complex-Targeting Curaxin CBL0137
Study Phase: Phase 1/Phase 2
A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Drug, Biological
Study Drugs: Cytarabine, Flotetuzumab
Study Phase: Phase 1
A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors
A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2026
Intervention Type: Drug
Study Drug: Elimusertib
Study Phase: Phase 1/Phase 2
Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Drug
Study Drug: Larotrectinib Sulfate
Study Phase: Phase 2
A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: April 13, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, Cytarabine, Fludarabine Phosphate, Methotrexate, Pevonedistat, Hydrocortisone
Study Phase: Phase 1
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Other
Study Drug: Selinexor
Study Phase: Phase 1
A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan
A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Other
Study Phase: Phase 1
A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: October 22, 2024
Intervention Type: Drug
Study Drugs: Irinotecan, Pevonedistat, Temozolomide
Study Phase: Phase 1
View 8 Less Clinical Trials

15 Total Publications

COVID-19 Reinfection in Children With Cancer: Clinical Course and Risk Factors.
COVID-19 Reinfection in Children With Cancer: Clinical Course and Risk Factors.
Journal: Pediatric blood & cancer
Published: May 19, 2025
Similar Doctors
Expertise in
26
conditions
Dr. Mariko Sato
Pediatric Hematology Oncology
Expertise in
26
conditions
Dr. Mariko Sato
Pediatric Hematology Oncology
Referral may be required
Before you request
1201 West La Veta Avenue, 
Orange, CA 
 (0.1 miles away)
714-509-8636
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mariko Sato is a Pediatric Hematologist Oncology provider practicing medicine in Orange, California. Dr. Sato is highly rated in 26 conditions, according to our data. Her clinical expertise encompasses Glioma, Medulloblastoma, Hepatoblastoma, Embryonal Tumor with Multilayered Rosettes, and Bone Marrow Aspiration. Dr. Sato is currently accepting new patients.

Expertise in
17
conditions
Dr. Diane J. Nugent
Pediatric Hematology Oncology
Expertise in
17
conditions
Dr. Diane J. Nugent
Pediatric Hematology Oncology
Referral required
Before you request
1201 West La Veta Avenue, 
Orange, CA 
 (0.1 miles away)
714-509-8636
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Diane Nugent is a Pediatric Hematologist Oncology provider practicing medicine in Orange, California. Dr. Nugent is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Blood Clots, Hemophilia A, Immune Thrombocytopenic Purpura (ITP), and Sickle Cell Disease. Dr. Nugent is currently accepting new patients.

Expertise in
16
conditions
Dr. Elyssa M. Rubin
Pediatric Hematology Oncology
Expertise in
16
conditions
Dr. Elyssa M. Rubin
Pediatric Hematology Oncology
Referral may be required
Before you request
1201 West La Veta Avenue, 
Orange, CA 
 (0.1 miles away)
714-509-8636
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Elyssa Rubin is a Pediatric Hematologist Oncology provider practicing medicine in Orange, California. Dr. Rubin is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Ewing Sarcoma, Osteosarcoma, Neuroblastoma, Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Aspiration. Dr. Rubin is currently accepting new patients.

Frequently Asked Questions about Dr. Josephine H. Haduong

How do I make an appointment with Dr. Josephine H. Haduong?

You can book an appointment with Dr. Josephine H. Haduong by calling their office at 714-509-8636. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Josephine H. Haduong a top-rated expert for Rhabdomyosarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Josephine H. Haduong is classified as an Advanced expert for Rhabdomyosarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Josephine H. Haduong specialize in?

While Dr. Josephine H. Haduong is a Pediatric Hematology Oncology, they have specific expertise in Rhabdomyosarcoma, Hepatoblastoma, and Acute Lymphoblastic Leukemia (ALL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatric Hematology Oncology.

Does Dr. Josephine H. Haduong participate in research or clinical trials?

Yes. Dr. Josephine H. Haduong has published 15 articles and abstracts on conditions like Rhabdomyosarcoma. You can view a list of Dr. Josephine H. Haduong's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Josephine H. Haduong accept my insurance?

Dr. Josephine H. Haduong accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 714-509-8636 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Haduong's expertise for a condition
ConditionClose
      View All 15 Advanced Conditions
      View All 35 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile